FDA Issues Boxed Warning for Adzynma Enzyme Replacement Therapy for cTTP
The U.S. Food and Drug Administration (FDA) has issued a new boxed warning for Adzynma, a recombinant ADAMTS13 enzyme replacement therapy approved for congenital thrombotic thrombocytopenic purpura (cTTP). This action comes after the agency identified a significant safety concern: the development of neutralizing antibodies, also known as blocking antibodies, which can prevent the drug from functioning effectively. In severe instances, this issue has led to tragic outcomes, including the death of a 7-year-old child.
Adzynma was approved by the FDA on November 9, 2023, as the first recombinant ADAMTS13 therapy for cTTP, a rare inherited blood disorder characterized by a severe deficiency of the ADAMTS13 enzyme, which is crucial for regulating blood clotting. The therapy contains two modified forms of the ADAMTS13 protein, one of which closely resembles the natural human version.
The FDA’s boxed warning is the most serious type of warning that can be mandated on a drug label and serves to inform healthcare providers and patients about the risks associated with the therapy. The agency has directed Takeda Pharmaceuticals, the manufacturer of Adzynma, to include this warning in the prescribing information. This warning emphasizes the potential for patients to develop blocking antibodies and the serious consequences that may arise from this condition, including the risk of death.
Patients currently receiving Adzynma are advised not to discontinue treatment without first consulting their healthcare provider. It is essential for healthcare providers to conduct regular laboratory tests on all patients to monitor for the presence of blocking antibodies as early as possible to mitigate risks.
The concerning safety signal regarding Adzynma was detected through the FDA's Adverse Event Reporting System (FAERS), a postmarketing surveillance database that collects reports of adverse events and medication errors from healthcare providers, manufacturers, and patients. This system enables the FDA to continuously monitor the safety profile of approved products and take necessary regulatory actions when new risks are identified.
In the reported fatal case, the child developed worsening neurologic symptoms approximately 10 months after starting prophylactic treatment with Adzynma. Neutralizing antibodies against ADAMTS13 were identified during this period, and the child had a prior history of severe allergic reactions to fresh frozen plasma. Following this incident, the FDA issued a Safety Communication to alert both patients and healthcare providers about the potential risks associated with the treatment.
The revised labeling for Adzynma now includes specific safety information and recommendations for monitoring, aiming to enhance patient safety and ensure that healthcare providers are aware of the risks involved with this enzyme replacement therapy.




